Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

Appl Health Econ Health Policy. 2022 Jul;20(4):623. doi: 10.1007/s40258-022-00734-z.

Authors

Sara Stafford¹, Peter G Bech², Adam Fridhammar³, Nino Miresashvili⁴, Andreas Nilsson³, Michael Willis³, Aiden Liu²

Affiliations

¹ Fraser Health Division of Endocrinology, 902-13737 96th Avenue, Surrey, BC, V3V 0C6, Canada. [email protected].
² Novo Nordisk Canada Inc., 2476 Argentia Rd, Mississauga, ON, L5N 6M1, Canada.
³ The Swedish Institute for Health Economics, Box 2127, 220 02, Lund, Sweden.
⁴ Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.

No abstract available

Publication types

Published Erratum